📊 PDSB Key Takeaways
Is PDS Biotechnology Corp (PDSB) a Good Investment?
PDS Biotechnology is a pre-revenue company burning $27.8M in annual operating cash with no profitability path visible in near-term fundamentals. With only $26.7M in cash reserves and negative operating margins of -31.5M, the company faces severe runway constraints and will require significant capital raises within the next 12 months, resulting in shareholder dilution. High leverage (Debt/Equity 2.16x) combined with no revenue generation presents substantial financial distress risk.
Why Buy PDS Biotechnology Corp Stock? PDSB Key Strengths
- Adequate current liquidity position with $26.7M cash on hand
- Current ratio of 2.98x provides near-term ability to meet obligations
- Zero capital expenditure suggests focused R&D spending without facility expansion
PDSB Stock Risks: PDS Biotechnology Corp Investment Risks
- Pre-revenue stage with -$34.5M net loss and no path to profitability shown in latest filings
- Severe cash burn rate of -$27.8M annually depletes cash runway to approximately 12 months
- Elevated debt-to-equity ratio of 2.16x with $20M long-term debt limits financial flexibility for capital raises
- Negative cash flow from operations indicates core business model not yet operational
Key Metrics to Watch
- Cash balance and months of runway remaining
- Operating cash flow burn rate trends quarter-over-quarter
- Debt service obligations and refinancing requirements
- Whether company achieves revenue generation or announces clinical milestones
PDS Biotechnology Corp (PDSB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.98x current ratio provides a solid financial cushion.
PDSB Profit Margin, ROE & Profitability Analysis
PDSB vs Healthcare Sector: How PDS Biotechnology Corp Compares
How PDS Biotechnology Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PDS Biotechnology Corp Stock Overvalued? PDSB Valuation Analysis 2026
Based on fundamental analysis, PDS Biotechnology Corp shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PDS Biotechnology Corp Balance Sheet: PDSB Debt, Cash & Liquidity
PDSB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PDS Biotechnology Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.03 indicates the company is currently unprofitable.
PDSB Revenue Growth, EPS Growth & YoY Performance
PDS Biotechnology Corp Dividends, Buybacks & Capital Allocation
PDSB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PDS Biotechnology Corp (CIK: 0001472091)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PDSB
What is the AI rating for PDSB?
PDS Biotechnology Corp (PDSB) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PDSB's key strengths?
Claude: Adequate current liquidity position with $26.7M cash on hand. Current ratio of 2.98x provides near-term ability to meet obligations.
What are the risks of investing in PDSB?
Claude: Pre-revenue stage with -$34.5M net loss and no path to profitability shown in latest filings. Severe cash burn rate of -$27.8M annually depletes cash runway to approximately 12 months.
What is PDSB's revenue and growth?
PDS Biotechnology Corp reported revenue of N/A.
Does PDSB pay dividends?
PDS Biotechnology Corp does not currently pay dividends.
Where can I find PDSB SEC filings?
Official SEC filings for PDS Biotechnology Corp (CIK: 0001472091) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PDSB's EPS?
PDS Biotechnology Corp has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PDSB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, PDS Biotechnology Corp has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PDSB stock overvalued or undervalued?
Valuation metrics for PDSB: ROE of -372.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PDSB stock in 2026?
Our dual AI analysis gives PDS Biotechnology Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PDSB's free cash flow?
PDS Biotechnology Corp's operating cash flow is $-27.8M, with capital expenditures of $0.0.
How does PDSB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -372.9% (avg: 15%), current ratio 2.98 (avg: 2).
Is PDS Biotechnology Corp carrying too much debt?
PDSB has a debt-to-equity ratio of 2.16x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.98 suggests adequate short-term liquidity.